公开(公告)号：US20220340577A1

公开(公告)日：2022-10-27

申请号：US17122543

申请日：2020-12-15

申请人： Merck Patent GmbH ,  Vertex Pharmaceuticals Incorporated

发明人： Andrew BAYLY ,  Matthew BLEICH ,  Jean-Damien CHARRIER ,  James DODD ,  Steven DURRANT ,  Meredith Suzanne ENO ,  Gorka ETXEBARRIA I JARDI ,  Simon EVERITT ,  Damien FRAYSSE ,  Shazia KELLY ,  Ronald KNEGTEL ,  Igor MOCHALKIN ,  Michael MORTIMORE ,  Kiri NORTH ,  Filippos PORICHIS ,  Robert PULLIN ,  Alistair RUTHERFORD ,  Pierre-Henri STORCK ,  Heather Clare TWIN

IPC分类号： C07D487/04 ,  A61P35/00 ,  C07D513/04 ,  C07D519/00

摘要： The present invention provides compounds, compositions thereof, and methods of using the same.

公开(公告)号：US20230271963A1

公开(公告)日：2023-08-31

申请号：US17847938

申请日：2022-06-23

申请人： Vertex Pharmaceuticals Incorporated

发明人： Nadia AHMAD ,  Dean BOYALL ,  Jean-Damien CHARRIER ,  Chris DAVIS ,  Rebecca DAVIS ,  Steven DURRANT ,  Gorka ETXEBARRIA I JARDI ,  Damien FRAYSSE ,  Juan-Miguel JIMENEZ ,  David KAY ,  Ronald KNEGTEL ,  Donald MIDDLETON ,  Michael O'DONNELL ,  Maninder PANESAR ,  Francoise PIERARD ,  Joanne PINDER ,  David SHAW ,  Pierre-Henri STORCK ,  John STUDLEY ,  Heather TWIN

IPC分类号： C07D487/04 ,  C07D453/02 ,  C07D471/08 ,  C07D487/08 ,  C07D491/107 ,  C07D498/04 ,  C07D498/10

CPC分类号： C07D487/04 ,  C07D453/02 ,  C07D471/08 ,  C07D487/08 ,  C07D491/107 ,  C07D498/04 ,  C07D498/10

摘要： The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.
The compounds of this invention have formula I:




or a pharmaceutically acceptable salt, wherein the variables are as devined herein.
Moreover, The compounds of this invention have formula I-A:




or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

公开(公告)号：US20210047333A1

公开(公告)日：2021-02-18

申请号：US17007412

申请日：2020-08-31

申请人： Vertex Pharmaceuticals Incorporated

发明人： Nadia AHMAD ,  Dean BOYALL ,  Jean-Damien CHARRIER ,  Chris DAVIS ,  Rebecca DAVIS ,  Steven DURRANT ,  Gorka ETXEBARRIA I JARDI ,  Damien FRAYSSE ,  Juan-Miguel JIMENEZ ,  David KAY ,  Ronald KNEGTEL ,  Donald MIDDLETON ,  Michael O'DONNELL ,  Maninder PANESAR ,  Francoise PIERARD, Marie ,  Joanne PINDER ,  David SHAW ,  Pierre-Henri STORCK ,  John STUDLEY ,  Heather TWIN

IPC分类号： C07D487/04 ,  C07D453/02 ,  C07D471/08 ,  C07D487/08 ,  C07D491/107 ,  C07D498/04 ,  C07D498/10

摘要： The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.
The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein.
Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.